Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

Pacira BioSciences, Inc.

Pacira Pharmaceuticals, Inc. focuses on providing non-opioid medications and advanced drug delivery technologies for pain management.

msh id	COM:PACIRA
symbol	PCRX
name	Pacira BioSciences, Inc.
homepage url	https://www.pacira.com
country	US
sector	Healthcare
industry	Drug Manufacturers - Specialty & Generic
market	STOCKS
employee count	711
crunchbase url	-
linkedin url	-
founders	-

market cap	946.75M
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-0.01
growth cost of revenue	0.21
growth depreciation and amortization	0.23
growth ebitda	0.34
growth ebitda ratio	0.32
growth eps	-
growth eps diluted	-
growth general and administrative expenses	0.06
growth gross profit	-0.07
growth gross profit ratio	-0.08

COM:PACIRA

Pacira Pharmaceuticals, Inc.

Last Close

17.03

21/11 21:00

Market Cap

946.75M

Beta: -

Volume Today

385.19K

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	587.66M
cost of revenue	587.66M
depreciation and amortization	75.57M
ebitda	162.9M
ebitda ratio	0.24
eps	0.91
eps diluted	0.81
operating expenses	345.7M
operating income	87.32M
operating income ratio	0.13

accounts receivables	-7.16M
capital expenditure	-15.16M
cash at beginning of period	104.14M
cash at end of period	153.3M
inventory	104.35M
working capital ttm	353.59M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-